[go: up one dir, main page]

PE20061355A1 - Composicion farmaceutica que comprende ramelteon - Google Patents

Composicion farmaceutica que comprende ramelteon

Info

Publication number
PE20061355A1
PE20061355A1 PE2006000359A PE2006000359A PE20061355A1 PE 20061355 A1 PE20061355 A1 PE 20061355A1 PE 2006000359 A PE2006000359 A PE 2006000359A PE 2006000359 A PE2006000359 A PE 2006000359A PE 20061355 A1 PE20061355 A1 PE 20061355A1
Authority
PE
Peru
Prior art keywords
ramelteon
fluoxetine
pharmaceutical composition
composition including
miltalopran
Prior art date
Application number
PE2006000359A
Other languages
English (en)
Inventor
Keisuke Hirai
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37073564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20061355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20061355A1 publication Critical patent/PE20061355A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE (S)-N-[2-(1,6,7,8-TETRAHIDRO-2H-INDEN[5,4-b]FURAN-8-IL)ETIL]PROPIONAMIDA, TAMBIEN DENOMINADO RAMELTEON, EL CUAL ES UN AGONISTA DE MELATONINA, Y A UNA COMBINACION QUE COMPRENDE RAMELTEON Y UNA O MAS DROGAS SELECCIONADAS DE ANTIDEPRESIVOS O ANTIANSIEDAD TALES COMO FLUOXETINA, SERTRALINA, PAROXETINA, MIANSERIN, MILNACIPRAN, CITALOPRAM, ESCITALOPRAM, FLUVOXAMIDA, MINAPRINA, DULOXETINA, ENTRE OTROS. ESTA COMPOSICION ES UTIL PARA LA PREVENCION O TRATAMIENTO DE DEPRESION O DESORDENES DE ANSIEDAD DE PACIENTES QUE TIENEN ANTECEDENTES DE DIABETES, HIPERLIPIDEMIA, HIPERTENSION O SINDROME METABOLICO
PE2006000359A 2005-04-04 2006-04-03 Composicion farmaceutica que comprende ramelteon PE20061355A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005107674 2005-04-04

Publications (1)

Publication Number Publication Date
PE20061355A1 true PE20061355A1 (es) 2007-01-15

Family

ID=37073564

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000359A PE20061355A1 (es) 2005-04-04 2006-04-03 Composicion farmaceutica que comprende ramelteon

Country Status (23)

Country Link
US (1) US20090042861A1 (es)
EP (1) EP1867641A4 (es)
JP (1) JP5259181B2 (es)
KR (1) KR20070118103A (es)
CN (1) CN101189219A (es)
AR (1) AR054435A1 (es)
AU (1) AU2006231752B2 (es)
BR (1) BRPI0607684A2 (es)
CA (1) CA2602267A1 (es)
CL (1) CL2009000980A1 (es)
CR (1) CR9385A (es)
GE (1) GEP20105001B (es)
IL (1) IL186049A0 (es)
MA (1) MA29677B1 (es)
MY (1) MY142214A (es)
NO (1) NO20075599L (es)
NZ (1) NZ561677A (es)
PE (1) PE20061355A1 (es)
RU (1) RU2413510C2 (es)
TW (1) TWI391132B (es)
UA (1) UA89397C2 (es)
WO (1) WO2006107019A1 (es)
ZA (1) ZA200708445B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100331402A1 (en) * 2008-01-31 2010-12-30 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
US8426461B2 (en) 2011-01-17 2013-04-23 Takeda Pharmaceutical Company Limited Orally dispersible tablet
EA201391053A1 (ru) * 2011-01-17 2013-12-30 Такеда Фармасьютикал Компани Лимитед Таблетка, диспергируемая в ротовой полости
JP6061924B2 (ja) * 2011-10-14 2017-01-18 武田薬品工業株式会社 口腔内分散性製剤
CN102718675B (zh) * 2012-06-07 2015-03-25 上海右手医药科技开发有限公司 阿戈美拉汀甲磺酸复合物及其制备方法
RU2571546C1 (ru) * 2014-07-14 2015-12-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации Способ дифференцированной диагностики и терапии синдрома ночной еды
WO2018176109A1 (pt) 2017-03-30 2018-10-04 Penello Temporao Jose Eduardo Composição mulivítamínica para aprimoramento da fluência verbal, dimimuição dos sintomas da ansiedade de performance e seu método de preparação
CN108451917A (zh) * 2018-03-22 2018-08-28 仁和堂药业有限公司 高稳定性米安色林制剂的制备方法
CN113908165A (zh) * 2020-07-10 2022-01-11 上海日馨医药科技股份有限公司 一种药物组合物及其应用
WO2025018810A1 (ko) * 2023-07-18 2025-01-23 주식회사 지오비스타 동물에 대한 정신질환 또는 행동장애의 예방 또는 치료용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
DE69524871T2 (de) * 1994-06-10 2002-08-22 Smithkline Beecham P.L.C., Brentford Benzopyrans und deren verwendung als therapeutische mittel
US5780470A (en) * 1995-06-02 1998-07-14 Bristol-Myers Squibb Company Melatonergic indanyl piperazines
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
PL188093B1 (pl) * 1996-03-08 2004-12-31 Takeda Chemical Industries Ltd Związek trójpierścieniowy, sposób jego wytwarzania i zastosowanie, kompozycja farmaceutyczna oraz związki pośrednie
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
ATE247967T1 (de) * 1998-06-09 2003-09-15 Takeda Chemical Industries Ltd Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
JP3509637B2 (ja) * 1998-06-09 2004-03-22 武田薬品工業株式会社 睡眠障害予防治療剤
NZ523800A (en) * 2000-06-27 2005-02-25 Taisho Pharmaceutical Co Ltd Therapeutic preparation comprising a melanocortin receptor (MC4) antagonist or a piperazine derivative thereof for treating anxiety neurosis or depression
US6589978B2 (en) * 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
JP2005516891A (ja) * 2001-09-13 2005-06-09 シェーリング　コーポレイション アデノシンＡ２ａレセプタアンタゴニストと抗鬱薬または抗不安薬との組合せ
US20070088079A1 (en) * 2005-09-20 2007-04-19 Takeda Pharmaceutical Company Limited Prophylactic or therapeutic agent for sleep disorder

Also Published As

Publication number Publication date
RU2007140986A (ru) 2009-05-20
NO20075599L (no) 2007-12-19
TW200719885A (en) 2007-06-01
AU2006231752A1 (en) 2006-10-12
RU2413510C2 (ru) 2011-03-10
EP1867641A4 (en) 2010-01-13
CN101189219A (zh) 2008-05-28
CL2009000980A1 (es) 2009-08-14
AR054435A1 (es) 2007-06-27
MY142214A (en) 2010-11-15
NZ561677A (en) 2011-02-25
CA2602267A1 (en) 2006-10-12
UA89397C2 (ru) 2010-01-25
JPWO2006107019A1 (ja) 2008-09-25
ZA200708445B (en) 2009-03-25
KR20070118103A (ko) 2007-12-13
WO2006107019A1 (ja) 2006-10-12
GEP20105001B (en) 2010-06-10
BRPI0607684A2 (pt) 2009-09-22
JP5259181B2 (ja) 2013-08-07
EP1867641A1 (en) 2007-12-19
US20090042861A1 (en) 2009-02-12
AU2006231752B2 (en) 2012-03-01
TWI391132B (zh) 2013-04-01
MA29677B1 (fr) 2008-08-01
CR9385A (es) 2007-12-07
IL186049A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
PE20061355A1 (es) Composicion farmaceutica que comprende ramelteon
CL2007003065A1 (es) Compuestos derivados de benzodioxano, agonista 5ht2c, composicion farmaceutica que lois comprende; y sus uso en el tratamiento de un trastorno psicotico, ansiedad, depresion, trastorno bipolar, sindrome premenstrual, entre otros
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
EA200970956A1 (ru) Селективные модуляторы рецепторов андрогена для лечения диабета
CL2008001465A1 (es) Compuestos derivados de [2,1,3]benzoxadiazol-5-carboxamidas, moduladores de los receptores ampa; composiciones farmacéuticas; y su uso en el tratamiento de afecciones hipoglutamatérgicas, trastornos cognitivos, enfermedad de parkinson, adhd, síndrome de rett, depresión respiratoria, síndrome x frágil y enfermedad de alzheimer.
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
ATE528005T1 (de) 2s,4r ketoconazol zur behandlung von diabetes, metabolischem syndrom und anderen erkrankungen
GT200500284A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
ATE490779T1 (de) Y4-selektive rezeptoragonist für therapeutische interventionen
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2008002268A1 (es) Compuestos derivados de amidas, moduladores del receptor taar1; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, entre otros.
CL2007003640A1 (es) Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
CL2007003182A1 (es) Compuestos derivados de tetrahidrociclopenta[b]indol; composicion farmaceutica que los comprende; y su uso para tratar trastornos fisiologicos, tales como reduccion de masa osea, osteoporosis, osteopenia o reduccion de masa o fuerza muscular.
EA200601449A1 (ru) Применение агомелатина для получения лекарственных средств, предназначенных для лечения нарушений сна у пациента с депрессией
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
ATE454372T1 (de) Am histamin-h3-rezeptor wirksame mittel, herstellung und therapeutische anwendungen
PE20120324A1 (es) Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
Amidfar et al. Effect of co-administration of memantine and sertraline on the antidepressant-like activity and brain-derived neurotrophic factor (BDNF) levels in the rat brain
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
Rubio et al. Reboxetine adjunct for partial or nonresponders to antidepressant treatment
JP2007513052A5 (es)
TW200736612A (en) Human G protein-coupled receptor and modulators thereof for the treatment of obesity and donditions related thereto
AR045314A1 (es) Composiciones farmaceuticas de analepticos y antidepresivos
UA84692C2 (ru) Фармацевтическая композиция, содержащая арипипразол и ингибитор повторного усвоения серотонина, и ее использование для лечения расстройств настоения

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed